$2.700
+0.061 (+2.27%)終値時点
- High
- 2.750
- Open
- 2.560
- VWAP
- 2.67
- Vol
- 41.00K
- Mkt Cap
- —
- Low
- 2.550
- Amount
- 109.33K
- EV/EBITDA, TTM
- 0.00
SL Science Holding Ltd is a Taiwan-based company mainly engaged in the research and development (R&D) of cell and gene therapies for cancer treatment and regenerative medicine. The Company develops investigational immune cell technologies, including gamma delta (γδ) T cells, Armed-T cells and exosome-based formulations, and operates through its biotechnology and oncology research activities.
AI analysis of SL Science Holding Ltd (SLBT)
buySL Science Holding Ltd (SLBT) appears to be a good buy right now, primarily driven by its recent FDA filing for a new drug that could significantly impact its future revenue. The stock is currently priced at $2.70, with a recent RSI of 51.40 indicating a neutral momentum, which is favorable for potential upward movement. Additionally, the stock has shown a 5-day change of +1.89% and a 20-day change of +2.08%, reflecting positive short-term performance. However, investors should be cautious of the high debt-to-equity ratio of 882.89%, which poses a significant risk.
バリュエーション指標
ニュース
9.008-27NASDAQ.COMSL Science Holding Files New Drug Master File with FDA
9.008-27NewsfilterSL Science Files New Drug Master File with FDA
9.508-04NASDAQ.COMBiotech Stocks Surge with Significant Gains
- 8.507-17Newsfilter
SL Science Showcases γδ T Cell Therapy for Glioblastoma
- 8.507-14Newsfilter
SL Science Submits Orphan Drug Designation for Brain Cancer Treatment
SLBT FAQ — answered by Alphio AI
SL Science Holding Ltd is a Taiwan-based company mainly engaged in the research and development (R&D) of cell and gene therapies for cancer treatment and regenerative medicine. The Company develops investigational immune cell technologies, including gamma delta (γδ) T cells, Armed-T cells and exosome-based formulations, and operates through its biotechnology and oncology research activities. It operates in the Healthcare sector.
SL Science Holding Ltd (SLBT) appears to be a good buy right now, primarily driven by its recent FDA filing for a new drug that could significantly impact its future revenue. The stock is currently priced at $2.70, with a recent RSI of 51.40 indicating a neutral momentum, which is favorable for potential upward movement. Additionally, the stock has shown a 5-day change of +1.89% and a 20-day change of +2.08%, reflecting positive short-term performance. However, investors should be cautious of the high debt-to-equity ratio of 882.89%, which poses a significant risk.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。